Clinical trials: Neovascular Age-related Macular Degeneration, open to volunteers
Neovascular Age-related Macular Degeneration
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina.
- Trial name
- NCT07007065
- Testing
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Where
- 137 sites in United States, Austria and 15 more
- Volunteers
- 561 people
- Sponsor
- AbbVie
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
- Trial name
- Super Tuscan (NCT07205887)
- Testing
- Remigromig, Aflibercept 2.0 mg
- Where
- 55 sites in United States
- Volunteers
- 160 people
- Sponsor
- EyeBiotech Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
This Phase 3 study is evaluating the safety and efficacy of 4D-150 versus aflibercept in participants with neovascular age-related macular degeneration (nAMD).
- Trial name
- 4FRONT-2 (NCT07064759)
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 126 sites in United States, Argentina and 15 more
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Neovascular Age-related Macular Degeneration
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
- Trial name
- Sightspire (NCT06847542)
- Testing
- Susvimo PDS Implant, Ranibizumab
- Where
- 61 sites in Austria, Czechia and 11 more
- Volunteers
- 250 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration, nAMD
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular…
- Trial name
- NCT07614776
- Testing
- ABP 938 8 mg, Aflibercept (US) 8 mg
- Where
- 81 sites in United States, Czechia and 7 more
- Volunteers
- 304 people
- Sponsor
- Amgen
Neovascular (Wet) Age-Related Macular Degeneration
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD).
- Trial name
- OVERTURE (NCT07587515)
- Testing
- EYC-0305
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Eyconis INC.
Neovascular Age-related Macular Degeneration
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
- Trial name
- Belvedere (NCT04853251)
- Testing
- PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
- Where
- 52 sites in United States
- Volunteers
- 188 people
- Sponsor
- Genentech, Inc.
Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD)
MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration.
Age-related macular degeneration (AMD) is the major cause of legal blindness in developed countries. Intermediate AMD represents the most frequent stage.
- Conditions
- Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD), AMD Population - Intermediate or Advanced AMD, AMD and Macular Edema
- Trial name
- MIND-AMD (NCT07847151)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Neovascular Age-Related Macular Degeneration
Extension Study for the Port Delivery System With Ranibizumab (Portal)
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed…
- Trial name
- Portal (NCT03683251)
- Testing
- PDS Implant with Ranibizumab 100 mg/mL
- Where
- 165 sites in United States, Argentina and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- AQUARIUS (NCT07482176)
- Testing
- Ixo-vec, Aflibercept
- Where
- 79 sites in United States
- Volunteers
- 534 people
- Sponsor
- Adverum Biotechnologies, Inc.
Neovascular Age-related Macular Degeneration (AMD)
Progression Suppression and Retinal Regression in VEGF-resistant AMD
The goal of this clinical trial is to assess safety and efficacy in patients with Neovascular Age-related Macular Degeneration with no response to existing therapy.
- Trial name
- PRESERVE (NCT07005323)
- Testing
- Pars plana vitrectomy
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- PharmaBio Corporation
Neovascular (Wet) Age-Related Macular Degeneration
First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)
This is a first-in-human clinical trial evaluating the safety and tolerability of BETA-TT8 Ophthalmic Gel in people with wet age-related macular degeneration (AMD).
- Trial name
- BEyOND (NCT07766473)
- Testing
- BETA-TT8 ophthalmic gel 3.8% w/v
- Where
- 4 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Filamon LTD
Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration
Changes in Intraocular Pressure After Intravitreal Injection
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections introduce additional fluid volume into the eye, which can cause an acute, transient elevation in intraocular pressure (IOP).
- Conditions
- Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration, Retinal Vein Occlusion, Ocular Hypertension
- Trial name
- NCT07826286
- Volunteers
- 50 people
- Sponsor
- Assiut University
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Neovascular Age Related Macular Degeneration(nAMD)
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- ASCEND (NCT07798375)
- Testing
- VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration
- Volunteers
- 244 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Neovascular (Wet) Age-related Macular Degeneration
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD).
- Trial name
- NCT06346600
- Testing
- SKG0106
- Where
- 10 sites in United States, China
- Volunteers
- 83 people
- Sponsor
- Skyline Therapeutics
Neovascular Age-related Macular Degeneration
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD.
- Trial name
- NCT05986864
- Testing
- SKG0106
- Where
- 9 sites in United States, China
- Volunteers
- 68 people
- Sponsor
- Skyline Therapeutics (US) Inc.
Neovascular (Wet) Age-Related Macular Degeneration
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.
- Trial name
- NCT05197270
- Testing
- 4D-150 IVT, Aflibercept IVT
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 215 people
- Sponsor
- 4D Molecular Therapeutics
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
This is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular…
- Trial name
- NCT07776522
- Testing
- JWK001, Aflibercept (2.0 mg)
- Where
- 16 sites in China
- Volunteers
- 50 people
- Sponsor
- West China Hospital
Neovascular Age-related Macular Degeneration(nAMD), Wet Macular Degeneration
LEAP Strategy for Neovascular Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is a common eye disease that can cause blindness in older adults. The "wet" form of AMD, called neovascular AMD, happens when abnormal blood vessels grow under the retina and…
- Trial name
- LEAP (NCT07744204)
- Testing
- Laser photocoagulation, Anti-VEGF agents
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital